diagnost tool
preannounc strong beat major
morn orasur pre-announce big beat major manag
success call retir ceo doug michel age march
cfo/coo ron spair age later succeed doug april dr
stephen tang ph serv orasur chairman year spoke
manag today confirm decis retir entir
contempl time dr tang job pool
candid admit bit surpris time announc earlier
week call one sever compani could acquir
howev posit first impress dr tang possess rare mix
strong busi scientif acumen think serv well role
continu like reiter buy rate pt
time manag success absent get acquir think
thing perfect time regard ceo and/or cfo choos retir believ doug
michel ron spair long strong tenur helm leav
compani time strength posit announc hire dr tang
involv past year dr tang look bring collect
skill set technic busi leadership new role ceo orasur
strong pre-announce expect gener revenu least
y/i guid driven strong beat
molecular collect expect far
molecular collect fire overtook size infecti diseas
busi compani molecular collect busi gener
revenu growth y/i total segment grew
approxim y/i molecular collect record compani
revenu last quarter posit surpris
us molecular collect revenu overtaken infecti diseas revenu
two straight quarter believ like continu point forward
know segment growth continu partial illustr multi-year contract
largest custom includ also believ helix
start-up two quarter launch underappreci like strong
also confirm manag pleas entir
infecti diseas portfolio hcv hiv
incom new ceo steve tang dr stephen tang hold ph
biochem engin lehigh univers wharton school
upenn member board director sinc serv
chairman board sinc novemb sinc januari dr tang
serv presid ceo univers citi scienc center urban research
park busi incub own thirti lead univers medic school
health network
continu page
price close busi januari
orasur lead provid oral fluid diagnost rapid
point care infecti diseas specif hiv hcv
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
prior dr tang group vice presid gener manag life scienc
olympu america inc ran life scienc group olympu lead
brand instrument total solut vitro diagnost microscop
micro-imag enabl technolog translat person medicin
dr tang also serv ceo millennium cell hydrogen batteri fuel cell
compani took public yet met dr tang expect next
week expect ceo doug michel cfo/coo ron spair facilit smooth
cfo/coo search begin cfo/coo ron spair also chosen retir
compani later year mr spair specif retir date set
determin base time appoint new cfo
diagnost tool
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
canaccord genuiti estim compani report
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti inc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin januari et
date time product januari et
price target use multipl revenu estim discount back year discount rate
hold debt nearli million cash
pt use premium multipl adj ep estim assum y/i ep growth
risk achiev target price valuat
regulatori risk exist new test indic delay denial approv would neg affect compani commerci risk
exist product reimburs competit continu weak economi could inhibit growth orasur drug
abus test busi risk associ intern sale infecti diseas product risk relat fund hiv
particularli unit state competit risk gener hiv product dna genotek subsidiari larg
custom failur continu work would advers impact busi
believ key risk includ major new product launch novaseq instrument premium valuat excess
peer group risk associ demand pace novaseq placement hiseq unit decommiss
competit noise/tract though believ meaning competit risk well bay nih/govern budgets/
spend particularli foreign govern like japan genom research center regulatori risk fda addit
risk factor less concern includ typic medic technolog risk price instrument consum risk
associ move test clinic increas compani focu bioinformat long-term also
highlight spend scale helix
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
diagnost tool
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
